BUDECOT 0.5MG

Indications

• Asthma
• Chronic obstructive pulmonary disease (COPD)
• Allergic rhinitis
• Eosinophilic esophagitis

Dosage

Children: Refer to the BNF for Children for specific paediatric dosing recommendations.

Adults: Refer to the BNF for specific dosing guidelines.

Mechanism of action

Budesonide exerts its effects by binding to glucocorticoid receptors within the cytoplasm of target cells. This binding leads to the regulation of gene expression and subsequent synthesis of anti-inflammatory proteins, while inhibiting the expression of pro-inflammatory genes. The net effect is a reduction in inflammation and immune response in the airways, enhancing airway patency and reducing symptoms associated with asthma and COPD.

Pharmacodynamics

The pharmacodynamic effects of budesonide include decreased synthesis and release of inflammatory mediators such as cytokines and leukotrienes. It also inhibits the migration of inflammatory cells to the airways and decreases mucus production. These actions contribute to improved lung function and reduced symptoms of respiratory conditions.

Pharmacokinetics

Budesonide is rapidly absorbed following inhalation, with peak plasma concentrations occurring within 30 minutes to 2 hours. It has a high first-pass metabolism in the liver, resulting in a bioavailability of approximately 15-20% when inhaled. The elimination half-life is about 2 to 3 hours. The drug is primarily metabolized by the cytochrome P450 system, specifically CYP3A4, and is excreted mainly in the urine as metabolites, with less than 1% excreted unchanged.

Contra-indications

• Hypersensitivity to budesonide or any other component of the formulation
• Untreated systemic fungal infections

Adverse effects

• Oral thrush
• Hoarseness
• Cough
• Headache
• Nausea
• Respiratory infection
• Pneumonia
• Adrenal suppression
• Growth retardation in children

Interactions

• CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase the plasma concentration of budesonide
• CYP3A4 inducers (e.g., rifampicin, phenytoin) may decrease the effectiveness of budesonide

Precautions

• Use with caution in patients with active or quiescent pulmonary tuberculosis
• Monitor for signs of adrenal insufficiency
• Consider potential effects on growth in children
• Patients with hepatic impairment may require dose adjustment

Pregnancy

Budesonide is classified as category B. Animal studies have not shown teratogenic effects, but use should be limited to necessary cases during pregnancy.

Breast-feeding

Budesonide is excreted in breast milk, but is generally considered safe for use during breastfeeding as systemic absorption is low.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

• Inhalation aerosol
• Dry powder inhaler

Indications

• Antibiotic therapy
• Pain relief
• Reduction of fever
• Treatment of inflammation
• Nutritional supplementation

Dosage

Children: Refer to specific drug formulations and their respective guidelines for dosing.

Adults: Refer to specific drug formulations and their respective guidelines for dosing.

Mechanism of action

The mechanism of action for drugs in suspension varies depending on the active ingredient. For example, antibiotics in suspension may inhibit bacterial cell wall synthesis or protein synthesis, leading to bacterial cell death. The dispersed solid particles allow for a controlled release of the active drug once ingested, enhancing bioavailability and therapeutic effects.

Pharmacodynamics

Suspensions provide an alternative route for drug delivery, particularly for patients who have difficulty swallowing pills. The pharmacodynamic effects depend on the active ingredient; for instance, anti-inflammatory agents reduce inflammation by inhibiting cyclooxygenase enzymes, while antipyretics work by acting on the hypothalamus to lower fever.

Pharmacokinetics

The pharmacokinetics of a drug in suspension is influenced by the particle size of the suspended solids, the viscosity of the medium, and the solubility of the active ingredient. Generally, after administration, the active drug is released from the suspension and absorbed through the gastrointestinal tract, reaching peak plasma concentrations within a specific time frame, which varies by formulation and drug properties.

Pregnancy

Consult healthcare professionals before use, as safety may vary depending on the specific active ingredient in the suspension.

Breast-feeding

Consult healthcare professionals before use, as safety may vary depending on the specific active ingredient in the suspension.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.